查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
幹細胞治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，2018-2028F 按類型、細胞來源、按應用、最終用戶、地區、競爭細分
市場調查報告書
商品編碼
1355182

幹細胞治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，2018-2028F 按類型、細胞來源、按應用、最終用戶、地區、競爭細分

Stem Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Cell Source, By Application, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球幹細胞治療市場價值為 2.631 億美元，預計在預測期內將呈現強勁成長，到 2028 年複合年成長率為 9.8%。幹細胞治療也稱為再生醫學，可促進細胞的修復反應。透過利用幹細胞或其衍生物來治療生病、功能障礙或受傷的組織。它代表了器官移植的下一階段，以細胞取代有限的供體器官。幹細胞具有在人體內分化成各種細胞類型的能力，起到恢復機制的作用。幹細胞主要有兩種分類：胚胎幹細胞和成體幹細胞。幹細胞進一步分為兩大類：多能性細胞和專能細胞。源自胚胎或胎兒組織的多能幹細胞進行複製，並有助於中胚層、外胚層和內胚層（三個初級胚層）內細胞和組織的發育。

主要市場促進因素：

幹細胞治療技術不斷進步：

市場概況
預測期 2018-2028
2022 年市場規模 26107萬美元
2028 年市場規模 5.3344億美元
2023-2028 年複合年成長率 12.39%
成長最快的細分市場 同種異體移植
最大的市場 北美洲

幹細胞分離、擴增和分化技術的進步促進了幹細胞療法的進步。科學家目前正在探索不同來源的幹細胞，包括胚胎幹細胞、誘導性多能幹細胞（iPSC）和成體幹細胞。此外，基因編輯（例如 CRISPR）等新興技術有望提高幹細胞治療的精確度和有效性。人們對幹細胞療法的認知和可用性不斷提高，導致對創新和系統開發的需求不斷增加。市場參與者正在積極尋求合作，以加強其研發活動，旨在擴大發展中國家和已開發國家的幹細胞治療市場。大量資金投入細胞為基礎的研究，特別是誘導多能幹細胞領域。該技術涉及對成人幹細胞進行基因重編程以獲得胚胎樣幹細胞，成為市場上可行的替代方案。

幹細胞治療需求激增

幹細胞療法由於其在再生醫學中的潛力而獲得了相當大的關注和接受。它為治療各種疾病提供了希望，包括神經系統疾病、心血管疾病、骨科損傷和自體免疫疾病。幹細胞研究持續成長，導致監管機構批准的數量增加。因此，幹細胞治療市場在過去經歷了顯著成長，預計在預測期內將繼續成長。該領域正在進行的研究和開發活動也刺激了利用幹細胞進行基因和細胞治療的需求。此外，註冊臨床試驗數量的增加可能會對市場需求產生相當大的影響並推動銷售成長。

增加政府對研發活動的支持

在已開發國家和其他購買力強勁的國家，對創新藥物的需求預計在未來幾年將顯著成長。這些藥物有望治療各種疾病，包括心血管、神經和自體免疫疾病。由於這些疾病在全球範圍內的盛行率不斷增加，幹細胞治療或療法的市場預計將擴大。在資金增加的推動下，市場過去也出現了成長。雖然在治療中使用胚胎引起了倫理問題，但重要的是要承認它們在拯救生命方面的潛力。持續的開發努力產生了創新療法。 iPSC 被世界各地的研究人員廣泛用於進行癌症研究。該產品已用於針對帕金森氏症和阿茲海默症等疾病的臨床試驗，預計未來幾年市場將會成長。在大流行期間，研究人員專注於開發對抗 COVID-19 病毒的治療方法，其中幹細胞的使用顯示出了前景。為了加強幹細胞市場的研究活動，澳洲政府進行了大量投資，並為未來十年提供了全面的路線圖。

慢性疾病增加

慢性病是全球普遍存在的健康問題，影響著全球三分之一的成年人。這些病症包括一系列疾病，包括癌症、肌肉骨骼和神經系統疾病、慢性損傷以及心血管和胃腸道疾病。他們通常需要住院治療、長期殘疾、生活品質下降，甚至可能致命。

幹細胞已被用於治療病毒的各種臨床試驗，提供了改進的治療選擇並顯著減少了病例數。此外，再生醫學的使用可能在降低個體感染率方面發揮至關重要的作用。在臨床試驗增加和獲得監管機構必要批准的推動下，預計未來幾年該產品的需求將會成長。隨著全球慢性病盛行率的上升，對幹細胞治療的需求預計將擴大，未來將帶來有利的市場機會。

主要市場挑戰

高成本治療

開發和實施幹細胞療法涉及大量研究、臨床試驗和製造成本。研究、開發和生產相關的高成本可能會限制患者的可及性。細胞處理市場的擴張因其高成本而受到阻礙。隨著人們尋求最新的治療選擇，細胞治療作為一種治療選擇越來越受歡迎。儘管需求顯著增加，細胞治療仍然昂貴得令人望而卻步。光是關節注射一項的費用就高達 1,000 美元，而更複雜的手術可能高達 10 萬美元。在美國，預計 2020 年每位患者幹細胞治療的平均費用將在 4,000 美元至 8,000 美元之間。因此，幹細胞治療市場的成長受到治療成本上漲的限制。

與現有療法的競爭

幹細胞療法可能需要證明其優於現有療法，才能獲得醫療專業人員、保險公司和監管機構的認可。幹細胞療法通常被認為是各個醫學領域現有療法的潛在替代品或補充品。雖然幹細胞前景廣闊，但它們也面臨著與成熟治療方法的競爭和比較。幹細胞療法需要嚴格的測試和監管批准，以確保患者安全。幹細胞不可預測的行為以及對腫瘤形成或免疫反應等潛在副作用的擔憂，構成了在廣泛採用之前必須解決的挑戰。

主要市場趨勢

增加臨床試驗和研究

幹細胞治療領域的臨床試驗和研究可能會持續成長。隨著科學家更了解幹細胞行為並最佳化其使用，將產生更多證據來支持其對各種醫療狀況的功效和安全性。正在進行的研究可能會揭示幹細胞療法在各種醫療條件下的新的、多樣化的應用。隨著對幹細胞的了解加深，科學家可能會發現以前未被認知到的治療機會。

國際合作

全球研究人員和機構之間的合作可以加速幹細胞研究的進展。共享知識和資源可以帶來更快的進步和突破。幹細胞研究的進步可能會帶來更精確和個人化的治療。透過根據個別患者的具體需求和基因組成來客製化治療方案，研究人員可以增強治療效果並最大程度地降低潛在風險。臨床試驗的成功結果可以吸引投資並導致幹細胞療法的商業開發。這可以使這些治療方法更廣泛地為患者提供。

細分市場洞察

類型洞察

同種異體移植領域透過移植供體細胞為患者建立新的免疫系統，在 2022 年實現了最高的市場收入。這種治療方法為各種惡性和非癌性疾病提供了潛在的治療方法，包括急性白血病、慢性白血病、何杰金氏淋巴瘤、腎上腺腦白質營養不良、骨髓衰竭症候群等。

細胞來源洞察

脂肪組織來源的間質幹細胞細分市場將成為 2022 年的主要收入貢獻者，預計將在整個預測期內保持其在幹細胞治療市場的主導地位。這可以歸因於癌症患者數量的不斷增加、目標人口的擴大、有害輻射暴露的增加以及政府的舉措。相反，由於肌肉骨骼疾病等慢性和致命疾病的發病率上升，以及吸煙（包括被動吸煙）的增加，預計骨髓間質幹細胞細分市場在預測期內將呈現最高的市場成長。與癌症有關

區域洞察

根據區域分析，2022年北美地區在幹細胞治療市場中佔據最大佔有率。北美地區的主導地位可歸因於該地區主要市場參與者的存在、先進的醫療基礎設施、有前途的報銷和政府政策，以及提高人們對幹細胞療法的認知。這些因素促進了該地區幹細胞治療市場的成長。此外，由於旨在開發先進療法並為醫療保健專業人員和危重疾病患者提供更好解決方案的研發活動不斷增加，投資者對北美幹細胞治療市場高度感興趣。

在中國、日本和印度等國家合作投資該市場的新興製藥公司的推動下，亞太地區預計將成為下一個最大的成長市場。該地區也見證了小型新創公司進入幹細胞治療市場。正在進行的大規模臨床試驗和該地區幹細胞庫的存在預計將進一步擴大該市場的全球足跡。預計歐洲將成為市場下一個最大的地區。

主要市場參與者

  • 生物修復療法公司
  • 新基公司
  • ReNeuron Group Limited
  • Opexa 治療公司
  • Pluristem 治療公司
  • 幹細胞科技公司
  • 生物庫家族
  • 珍貴細胞國際有限公司
  • 中胚層有限公司
  • 塞內卡生物製藥股份有限公司

可用的客製化：

全球幹細胞治療市場報告根據給定的市場資料，技術科學研究根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：服務概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（同種異體移植、自體移植）
    • 依細胞來源分類（脂肪組織來源的間質幹細胞、骨髓來源的間質幹細胞、臍帶血/胚胎幹細胞）
    • 按應用（癌症、肌肉骨骼疾病、傷口和損傷、心血管疾病、其他）
    • 按最終使用者（醫院和外科中心、治療公司）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按細胞來源
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按細胞來源
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按細胞來源
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按細胞來源
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲幹細胞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按細胞來源
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非幹細胞療法
    • 沙烏地阿拉伯幹細胞療法
    • 阿拉伯聯合大公國幹細胞療法

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球幹細胞治療市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 應用程式產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Biorestorative Therapies Inc.
    • Celgene corporation
    • ReNeuron Group plc
    • Opexa Therapeutics, Inc.
    • Pluristem Therapeutics Inc
    • STEMCELL Technologies Inc.
    • Biovault family
    • Precious Cells International Ltd
    • Mesoblast Ltd
    • Seneca Biopharmaceuticals, Inc.

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 4488

The global stem cell therapy market was valued at USD 263.10 million in 2022 and is expected to demonstrate robust growth in the forecast period, with a CAGR of 9.8% through 2028. Stem cell therapy, also known as regenerative medicine, facilitates the repair response of diseased, dysfunctional, or injured tissue through the utilization of stem cells or their derivatives. It represents the next phase in organ transplantation, substituting limited availability of donor organs with cells. Stem cells have the ability to differentiate into various cell types within the human body, functioning as a restorative mechanism. There are two primary classifications of stem cells: embryonic stem cells and adult stem cells. Stem cells are further categorized into two major groups: pluripotent and multipotent. Pluripotent stem cells, derived from embryos or fetal tissues, undergo replication and contribute to the development of cells and tissues within the mesoderm, ectoderm, and endoderm-the three primary germ layers.

Key Market Drivers:

Increasing Technological Advancement in Stem Cell Therapeutics:

Market Overview
Forecast Period2018-2028
Market Size 2022USD 261.07 Million
Market Size 2028USD 533.44 Million
CAGR 2023-202812.39%
Fastest Growing SegmentAllogenic Transplants
Largest MarketNorth America

The progress of stem cell therapies has been facilitated by advancements in stem cell isolation, expansion, and differentiation techniques. Scientists are currently exploring different sources of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. Furthermore, emerging technologies such as gene editing (e.g., CRISPR) hold promise for improving the precision and effectiveness of stem cell-based treatments. The growing awareness and availability of stem cell therapies have led to an increasing demand for innovation and system development. Market players are actively seeking collaborations to enhance their research and development activities, aiming to expand the stem cell treatment market in both developing and developed nations. Substantial funding has been invested in cell-based research, particularly in the field of induced pluripotent stem cells. This technique involves genetic reprogramming of adult human stem cells to obtain embryonic-like stem cells, serving as a viable alternative in the market.

Surging Demand for Stem Cell Therapy

Stem cell therapy has garnered considerable attention and acceptance owing to its potential in regenerative medicine. It offers promise in the treatment of various conditions, including neurological disorders, cardiovascular diseases, orthopedic injuries, and autoimmune disorders. There has been a consistent growth in stem cell research, leading to an increase in approvals from regulatory authorities. Consequently, the market for stem cell therapy has experienced significant growth in the past and is expected to continue growing during the forecast period. Ongoing research and development activities in the field have also spurred demand for gene and cell treatments utilizing stem cells. Furthermore, the rising number of registered clinical trials is likely to have a considerable impact on market demand and drive sales growth.

Increasing in Government Support for Research and Development Activities

In developed nations and other countries with strong purchasing power, the demand for innovative medicines is expected to experience significant growth in the coming years. These medicines hold promise for the treatment of various disorders, including cardiovascular, neurological, and autoimmune conditions. The market for stem cell treatment or therapy is projected to expand due to the increasing prevalence of these diseases worldwide. The market has also witnessed growth in the past, fueled by heightened funding. While using embryos in treatment raises ethical concerns, it is important to acknowledge their potential in saving lives. Continuous and development efforts have yielded innovative therapies. iPSCs are widely utilized by researchers worldwide to conduct studies on cancer. This product has been employed in clinical trials targeting diseases such as Parkinson's and Alzheimer's, leading to a projected market growth in the coming years. During the pandemic, researchers focused on developing treatments for combating the COVID-19 virus, with the use of stem cells showing promise. To enhance research activities in the stem cell market, the Australian government has made significant investments and provided a comprehensive roadmap for the next decade.

Rising Chronic Disorders

Chronic diseases are prevalent health issues globally, affecting one out of every three adults worldwide. These conditions encompass a range of ailments including cancer, musculoskeletal and neurologic disorders, chronic injuries, and cardiovascular and gastrointestinal diseases. They often necessitate hospitalization, long-term disability, diminished quality of life, and can even be fatal.

Stem cells have been utilized in various clinical trials for treating the virus, offering improved treatment options and significantly reducing the number of cases. Furthermore, the use of regenerative medicines may play a vital role in decreasing the infection rate among individuals. Anticipated growth in demand for this product is expected in the upcoming years, driven by an increase in clinical trials and obtaining necessary approvals from regulatory authorities. With a rising prevalence of chronic diseases worldwide, the demand for stem cell therapy is projected to expand, presenting favorable market opportunities in the future.

Key Market Challenges

High-Cost Treatment

Developing and implementing stem cell therapies involves significant research, clinical trials, and manufacturing costs. The high costs associated with research, development, and production can limit accessibility for patients. The expansion of the cell treatment market has been hindered by its high cost. As individuals seek out the latest therapeutic options, cell treatments have gained popularity as a treatment choice. Despite the significant increase in demand, cell treatments remain prohibitively expensive. Joint injections alone can cost up to USD1,000, while more complex procedures may reach up to USD100,000. In the United States, the average cost of stem cell therapy is projected to range between USD4,000 and USD8,000 per patient in 2020. Consequently, the growth of the stem cell therapy market is constrained by the elevated cost of treatment.

Competition with Established Therapies

Stem cell therapies may need to demonstrate superiority over existing treatments to gain acceptance from medical professionals, insurers, and regulatory bodies. Stem cell therapies are often considered as potential alternatives or complements to established therapies in various medical fields. While stem cells hold great promise, they also face competition and comparisons with well-established treatment approaches. Stem cell therapies require rigorous testing and regulatory approval to ensure patient safety. The unpredictable behavior of stem cells and concerns about potential side effects, such as tumor formation or immune responses, pose challenges that must be addressed before widespread adoption.

Key Market Trends

Increased Clinical Trials and Research

The field of stem cell therapy is likely to see continued growth in clinical trials and research studies. As scientists better understand stem cell behavior and optimize their use, more evidence will be generated to support their efficacy and safety for various medical conditions. Ongoing research will likely reveal new and diverse applications for stem cell therapy across various medical conditions. As the understanding of stem cells expands, scientists may identify previously unrecognized opportunities for treatment.

International Collaboration

Collaboration among researchers and institutions on a global scale could accelerate progress in stem cell research. Shared knowledge and resources could lead to faster advancements and breakthroughs. Advances in stem cell research could lead to more precise and personalized therapies. By tailoring treatments to individual patients based on their specific needs and genetic makeup, researchers can enhance therapeutic outcomes and minimize potential risks. Successful outcomes from clinical trials could attract investment and lead to the commercial development of stem cell therapies. This could make these treatments more widely available to patients.

Segmental Insights

Type Insights

The allogenic transplants segment achieved the highest market revenue in 2022 by establishing a new immune system for patients through engraftment of donor cells. This therapeutic approach offers potential treatment for various malignant and non-cancerous disorders including acute leukemia, chronic leukemia, Hodgkin's lymphoma, adrenoleukodystrophy, bone marrow failure syndromes, and more.

The rising number of cancer patients has stimulated the demand for Omidubicel, an advanced cell therapy specifically designed for individuals with blood cancer. Notably, in 2022, the Managing Director of Duke Cancer Institute acknowledged the efficacy of allogenic stem cell transplant using the novel cell therapy Omidubicel in a phase 3 trial (NCT02730299), surpassing the standard myeloablative umbilical cord blood treatment.

The growth of this segment can be attributed to factors such as cost-effectiveness and the expansion of stem cell banking. Additionally, numerous cell therapy companies are redirecting their focus towards the development of allogenic cell therapy products, which is expected to further propel the expansion of this segment.

Cell Source Insights

The adipose tissue-derived mesenchymal stem cells segment emerged as the primary revenue contributor in 2022 and is expected to maintain its dominance throughout the forecast period in the stem cell therapy market. This can be attributed to the growing number of cancer patients, as well as the expanding target population, increased exposure to harmful radiation, and government initiatives. Conversely, the bone marrow-derived mesenchymal stem cells segment is projected to exhibit the highest market growth during the forecast period, driven by a higher incidence of chronic and fatal diseases like musculoskeletal disorders, and the rise in tobacco smoking, including passive smoking, which is associated with cancer

Regional Insights

Based on regional analysis, North America accounted for the largest share in the stem cell therapy market in 2022. The dominance of the North America region can be attributed to the presence of major market players in the region, advanced healthcare infrastructure, promising reimbursement and government policies, as well as increasing awareness about stem cell therapies among the population. These factors contribute to the growth of the stem cells therapy market in this region. Moreover, investors are highly attracted to the stem cells therapy market in North America due to the rising research and development activities aimed at developing advanced therapies and providing better solutions to healthcare professionals and patients with critical disorders.

The Asia Pacific region is expected to be the next largest growing market, driven by the presence of emerging pharmaceutical companies collaborating in countries such as China, Japan, and India to invest in this market. The region also witnesses the entry of small start-ups in the stem cell therapy market. Ongoing large-scale clinical trials and the presence of stem cell banks in the region are expected to further expand the market's global footprint. Europe is anticipated to be the next largest region in the market.

Key Market Players

  • Biorestorative Therapies Inc.
  • Celgene Corporation
  • ReNeuron Group plc
  • Opexa Therapeutics, Inc.
  • Pluristem Therapeutics Inc
  • STEMCELL Technologies Inc.
  • Biovault family
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Seneca Biopharmaceuticals, Inc.

Report Scope:

In this report, the Global Stem Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stem Cell Therapy Market, By Type:

  • Allogenic Transplants
  • Autologous Transplants

Stem Cell Therapy Market, By Cell Source:

  • Adipose Tissue-Derived Mesenchymal Stem Cells
  • Bone Marrow-Derived Mesenchymal Stem Cells
  • Cord Blood/Embryonic Stem Cells

Stem Cell Therapy Market, By Application:

  • Cancer
  • Musculoskeletal Disorder
  • Wounds and Injuries
  • Cardiovascular Disease
  • Others

Stem Cell Therapy Market, By End User:

  • Hospitals and Surgical Centres
  • Therapeutic Companies

Stem Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stem Cell Therapy Market.

Available Customizations:

Global Stem Cell Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Allogenic Transplants, Autologous Transplants)
    • 5.2.2. By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells)
    • 5.2.3. By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Others)
    • 5.2.4. By End User (Hospitals and Surgical Centres, Therapeutic Companies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Stem Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Cell Source
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stem Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Cell Source
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Stem Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Cell Source
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Stem Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Cell Source
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Stem Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Cell Source
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Stem Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Cell Source
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Stem Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Cell Source
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Stem Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Cell Source
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. France Stem Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Cell Source
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Stem Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Cell Source
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Stem Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Cell Source
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stem Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Cell Source
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Stem Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Cell Source
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Stem Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Cell Source
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Stem Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Cell Source
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Stem Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Cell Source
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Stem Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Cell Source
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stem Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Cell Source
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Stem Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Cell Source
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Stem Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Cell Source
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Stem Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Cell Source
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stem Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Cell Source
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Stem Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Cell Source
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Stem Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Cell Source
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Stem Cell Therapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Biorestorative Therapies Inc.
    • 14.5.2. Celgene corporation
    • 14.5.3. ReNeuron Group plc
    • 14.5.4. Opexa Therapeutics, Inc.
    • 14.5.5. Pluristem Therapeutics Inc
    • 14.5.6. STEMCELL Technologies Inc.
    • 14.5.7. Biovault family
    • 14.5.8. Precious Cells International Ltd
    • 14.5.9. Mesoblast Ltd
    • 14.5.10. Seneca Biopharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer